U.S. FDA gives green signal for the first generic EpiPen alternative
Date: 2018-08-17   Author: Saif Ali Bepari  Category: #technology

U.S. FDA gives green signal for the first generic EpiPen alternative

The U.S. FDA has reportedly announced that it has provided the approval for an alternative of the generic EpiPen that has been touted to help individuals with severe allergies. According to sources, the generic EpiPen alternate has been developed by the U.S. arm of an Israeli company – Teva Pharmaceuticals.

For the uninitiated, Teva’s alternative is reportedly deemed to be an equivalent of the EpiPen and can be automatically substituted for the EpiPen & EpiPen Jr. prescriptions at the pharmacy counter.

According to an official press release by the FDA, the new alternative is an auto-injector for treating allergic reactions in an emergency including life threatening situations like anaphylaxis and is meant for children & adults who are above 33 pounds (minimum weight limit).

FDA Commissioner & M.D. Scott Gottlieb stated that the approval is a part of the FDA’s long-standing commitment of making affordable, safe and effective alternatives for different medicines commercially available. Gottlieb further added that individuals requiring access to the life-saving epinephrine because of their severe allergies now have an affordable, FDA certified alternative.

According to reports, EpiPens, manufactured by pharma giant Mylan, is currently experiencing a shortfall due to major manufacturing and supply issues. In consequence, EpiPens made it to the FDA’s list of drug shortages list on the 9th of May 2018. In the backdrop of this scenario, the new alternative from Teva is certain to be a lifesaver, claim experts familiar with the matter.

Incidentally, the EpiPen alternative had to undergo a rigorous trial to receive the approval from the FDA. One of the main reasons behind the delay for approval has been speculated to be the drug’s nature that is complex generic – in the sense, the product is inclusive of both, a drug and an injector device.

The approval is a victory for the FDA as the Trump administration strives to achieve their promise of lowering medicine prices.



About Author


Saif Ali Bepari

Saif Ali Bepari

Saif currently works as a content writer at Algosonline. A Computer Science graduate who has a zest for writing over coding, commenced his journey in the writing industry as a freelancer. Having had a prior freelance experience, he has tinkered with creative writing, ...

Read More

More from Saif


Post Recommendents

Video Surveillance Equipment Technology Market Size & Share to See Modest Growth Through 2023
Author: Partha Ray

' Video Surveillance Equipment Technology Market forecast report now available with Market Study Report encompasses an exhaustive study of this business space with regards to pivotal industry drivers, market share analysis, and the latest trends c...


Energy-as-a-Service (EaaS) Market Size & Share to See Modest Growth Through 2023
Author: Partha Ray

Global Energy-as-a-Service (EaaS) Market Report is a systematically conducted exhaustive study of the Global Energy-as-a-Service (EaaS) market. The aim of the Global Energy-as-a-Service (EaaS) Market report is to assist novice as well as seeded pl...


Smart Highway Construction Market Forecast to 2023: Top Companies, Growth Factors and Trend Forecast to 2023
Author: Partha Ray

The report Smart Highway Construction Market Research highlights key dynamics of Global Smart Highway Construction sector. The potential of the Smart Highway Construction Market has been investigated along with the key challenges. The current Mark...